Article

Vial launches VialConnect: Modernized CTMS with patient recruitment assistance

The company's VialConnect is an intuitive clinical trials management platform built for coordinators and investigators.

Vial this week announced the debut of VialConnect, an intuitive clinical trials management platform built for coordinators and investigators.

According to the company, VialConnect is offered at no cost and makes it simple for research sites to access Vial’s modernized CTMS and additional services for patient recruitment.

The company noted in a news release that signing up for VialConnect gives sites access to 2 services for free: First, a customizable CTMS (clinical trials management system) that powers core workflows and provides operational visibility. And second, A HIPAA-compliant EMR filtering tool making it easier to sort potential trial subjects.

"Since implementing Vial's CTMS at our sites, our team's day-to-day operations have become faster and more efficient,” Stacey Gomez, a clinical research manager and one of the first users said in a statement. “We can easily schedule new appointments, track patients, and view all of our studies in one place. It's easy to navigate and our team loves it.”

Simon Burns, co-founder and CEO of Vial, noted that the company talked extensively with PIs and CRCs to identify their main pain points — the lack of an intuitive CTMS and an inability to recruit patients efficiently.

VialConnect solves these issues through modernized tech solutions,” he said in the release. “After deploying VialConnect at our 30+ partner sites, it’s clear from their feedback that our CTMS and patient recruitment program wins in all of these areas.”

Vial strives to be a next generation site management organization by providing the necessary resources for research practices to run trials with faster execution and higher quality.

The company has over 90 employees and is based in San Francisco, California.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
© 2025 MJH Life Sciences

All rights reserved.